deltatrials
Completed PHASE1 NCT00942682

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Sponsor: Bayer

Conditions Carcinoid Tumor Neuroendocrine Tumor Pancreatic Neuroendocrine Tumor
Interventions RAD001 Sorafenib
Updated 6 times since 2017 Last updated: Apr 27, 2014 Started: Jul 31, 2009 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

A PHASE1 clinical study on Carcinoid Tumor and Neuroendocrine Tumor, this trial is completed. The trial is conducted by Bayer and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Dana-Farber Cancer Institute
  • Novartis
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States